Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 736 B
EBIT 2018 -
Net income 2018 161 B
Debt 2018 742 B
Yield 2018 2,91%
Sales 2019 1 754 B
EBIT 2019 -
Net income 2019 141 B
Debt 2019 688 B
Yield 2019 2,91%
P/E ratio 2018 29,77
P/E ratio 2019 32,70
EV / Sales2018 3,24x
EV / Sales2019 3,18x
Capitalization 4 888 B
More Financials
Company
Takeda Pharmaceutical Co., Ltd. is a research-based global pharmaceutical company that engages in the manufacture, sale, import, export, and marketing of pharmaceutical drugs.It operates through the following segments: Ethical Drug, Consumer Healthcare, and Others.The Ethical Drugs segment includes... 
Sector
Pharmaceuticals
Calendar
12/11Presentation
More about the company
Surperformance© ratings of Takeda Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on TAKEDA PHARMACEUTICAL CO L
12/08 BLUEBIRD BIO : TC BioPharm in gamma delta CAR T deal
12/07 TAKEDA PHARMACEUTICAL : Initiates Phase 1 Clinical Trial of Zika Vaccine Candida..
12/07 TAKEDA PHARMACEUTICAL : Appoints Toshio Fujimoto, MD, MBA, as General Manager of..
12/07 TAKEDA PHARMACEUTICAL : Patent Issued for Fumagillol Derivatives (USPTO 9827255)
12/07 BIOCENTURY - MANAGEMENT TRACKS : Sunesis, Vital
12/06 OVID THERAPEUTICS : Announces TAK-935 OV935 Has Received Orphan Drug Designation..
12/05 BIOCENTURY - MANAGEMENT TRACKS : Athenex, Biogen
12/04 TAKEDA PHARMACEUTICAL : Appoints Toshio Fujimoto, MD, MBA, as General Manager of..
12/04 TAKEDA PHARMACEUTICAL : Announces the Sale of the Tokyo Building Currently Used ..
12/03 TAKEDA PHARMACEUTICAL : Appoints Toshio Fujimoto, MD, MBA, as General Manager of..
More news
Sector news : Pharmaceuticals - NEC
11:03aDJMERCK : Appoints Allan Gabor as Managing Director in China
08:42aDJGLAXOSMITHKLINE : Encouraged By Blood-Cancer Drug Study
07:32aDJSANOFI : Receives U.S. FDA Approval for Insulin Injection Admelog
12:56a Monsanto offers cash to U.S. farmers who use controversial chemical
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/04 Is Allergan The Best Buy If You (Or Your Portfolio) Are Depressed?
11/29 HOLD ON TO NEKTAR THERAPEUTICS : There Is Much More Ammunition Left In Its Partn..
11/22 Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018
11/17 Takeda and Cognition Kit to present data on use of Apple Watch by MDD patient..
11/17 Takeda Pharmaceutical (TKPYY) Presents At Jefferies 2017 London Healthcare Co..
Chart TAKEDA PHARMACEUTICAL CO L
Duration : Period :
Takeda Pharmaceutical Co L Technical Analysis Chart | 4502 | JP3463000004 | 4-Traders
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 6 634  JPY
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
James Kehoe Director, Chief Financial & Corporate Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Shinji Ninomiya Manager-Research & Development
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD27.82%43 072
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659